Navigation Links
Mapping of protein inhibitors facilitates development of tailor-made anticancer agents
Date:2/21/2012

A team of researchers at Karolinska Institutet in Sweden has generated a map over the effects of small drug-like molecules on PARP1 and other similar proteins in the body. This map may explain the mechanism behind putative side effects of the so-called PARP inhibitors, and can play an important role in the development of novel tailor-made cancer drugs. The study is presented in the journal Nature Biotechnology, and will hopefully contribute to new cancer therapies with fewer detrimental side effects.

PARP1 is a protein with enzymatic activity that governs repair of DNA damage in our cells. In the past decade, PARP1 has been in the focus for a large number of industrial drug development projects, primarily targeting breast and ovarian cancers. More than 50 clinical studies have been initiated around the world.

In the current study, the researchers at Karolinska Institutet have tested the effects of small drug-like molecules inhibitors on PARP1 and other enzymes of the same class. The effects of 180 substances on 13 different human PARP enzymes were studied. Many of the drugs that are currently being tested in clinical studies were part of the survey.

"Our results give us a map over the effects of a number of known but also less well characterized drug-like compounds on different PARP enzymes", says Herwig Schler, who headed the study at the Department of Medical Biochemistry and Biophysics. "Studying the cross-reactivity of less well characterized compounds on different PARP enzymes is especially interesting, since it can give clues to the interpretation of clinical side effects."

The chemical interaction map was complemented with high-resolution structural information, showing at atomic detail how inhibitors bind to these PARP enzymes. Together, the results give unique insights into specificity and cross-reactivity of PARP inhibitors. This in turn will be an important hallmark toward development of selective PARP inhibitors tailor-made substances that can inhibit one PARP enzyme while leaving the others unaffected.

This project builds upon a long-standing industry collaboration that Karolinska Institutet has participated in within the Structural Genomics Consortium 2005-2010. The study published in Nature Biotechnology is the result of collaboration between the research group at KI, the University of Perugia (Italy), Actar AB, and GE Healthcare.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts
2. Fast new method for mapping blood vessels may aid cancer research
3. Blood vessel mapping reveals 4 new ZIP codes
4. Gene Mapping Reveals Clues to Bedbugs Pesticide Resistance
5. Roadmap published for dynamic mapping of estrogen signaling in breast cancer
6. Mapping faculty social networks helps female faculty move ahead at NJIT
7. Mapping a brain atlas
8. ELLKAY Introduces Revolutionary Live Insurance Mapping Solution for Diagnostic Laboratories
9. A single protein helps the body keep watch over the Epstein-Barr virus
10. CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
11. Protein structures give disease clues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... Zurich, Switzerland (PRWEB) , ... June 27, 2017 , ... ... crowd to manage token assets on the Ethereum blockchain, has released their technical ... but until now, there has been little systematic approach for determining which offerings will ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... to an upcoming case studies guidebook. This guidebook offers an excellent branding and ... will include articles, case studies and how-to’s that fall into the following categories:, ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/8/2017)... , June 8, 2017  StatLab Medical ... developer and manufacturer of diagnostic supplies for ... that Cressey & Company LP ("Cressey & ... completed a growth-focused investment in the Company. ... ownership position from selling shareholder, Prairie Capital, ...
Breaking Medicine Technology: